Management of Hormone Receptor-positive, HER2-negative Early Breast Cancer

Overview

Journal Semin Oncol

Specialty Oncology

Date 2020 Jun 18

PMID 32546323

Citations 20

Authors

Elaine M Walsh

Karen L Smith

Vered Stearns

Affiliations

Soon will be listed here.

Abstract

The majority of breast cancers are diagnosed at an early stage and are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Significant advances have been made in the management of early stage HR-positive, HER2-negative breast cancer, resulting in improved survival outcomes. In this review, we discuss important factors to consider in the management of this disease. In particular, we discuss the role of adjuvant endocrine therapy, specific endocrine therapy agents, the duration of adjuvant endocrine therapy, treatment-related side effects, and the role of genomic assays and other biomarkers when considering treatment recommendations for individuals with HR-positive, HER2-negative early breast cancer. Finally, we address emerging data to individualize therapeutic decision-making and provide future considerations.

Citing Articles

Preferences of patients with high-risk HR + /HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany.

Wockel A, Park-Simon T, Korfel A, Raab K, Tesch H Breast Cancer Res Treat. 2025; .

PMID: 39976865 DOI: 10.1007/s10549-025-07622-9.

Optimizing Premenopausal Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Management in India: Insights From Expert Consensus.

Vaid A, Pagani O, Ramesh A, Bharthuar A, Desai C, Biswas G Cureus. 2025; 16(12):e76392.

PMID: 39867062 PMC: 11763344. DOI: 10.7759/cureus.76392.

Serum Cholesterol Level Changes during Gonadotropin-Releasing Hormone-Agonist Therapy in Premenopausal Female Patients with Breast Cancer.

Choi S, Kim J, Lee S, Kim S, Chae H J Menopausal Med. 2024; 30(2):120-125.

PMID: 39315503 PMC: 11439570. DOI: 10.6118/jmm.24009.

Insights Into the Patient Experience of Hormone Therapy for Early Breast Cancer Treatment Using Patient Forum Discussions and Natural Language Processing.

Sreenivasan S, Fang C, Flood E, Markuzon N, Sze J JCO Clin Cancer Inform. 2024; 8:e2400038.

PMID: 39102642 PMC: 11371083. DOI: 10.1200/CCI.24.00038.

SMAD4 depletion contributes to endocrine resistance by integrating ER and ERBB signaling in HR + HER2- breast cancer.

Li K, Shu D, Li H, Lan A, Zhang W, Tan Z Cell Death Dis. 2024; 15(6):444.

PMID: 38914552 PMC: 11196642. DOI: 10.1038/s41419-024-06838-9.

References

Denkert C, Budczies J, von Minckwitz G, Wienert S, Loibl S, Klauschen F . Strategies for developing Ki67 as a useful biomarker in breast cancer. Breast. 2015; 24 Suppl 2:S67-72. DOI: 10.1016/j.breast.2015.07.017. View

Sun L, Brentnall A, Patel S, Buist D, Bowles E, Evans D . A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. JAMA Oncol. 2019; 5(12):1718-1730. PMC: 6777250. DOI: 10.1001/jamaoncol.2019.3323. View

Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M . Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007; 369(9574):1711-23. DOI: 10.1016/S0140-6736(07)60778-8. View

Goel S, Sharma R, Hamilton A, Beith J . LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev. 2009; (4):CD004562. PMC: 6513034. DOI: 10.1002/14651858.CD004562.pub4. View

Leung S, Nielsen T, Zabaglo L, Arun I, Badve S, Bane A . Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer. 2017; 2:16014. PMC: 5515324. DOI: 10.1038/npjbcancer.2016.14. View

Burstein H, Lacchetti C, Anderson H, Buchholz T, Davidson N, Gelmon K . Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol. 2016; 34(14):1689-701. DOI: 10.1200/JCO.2015.65.9573. View

Richman J, Ring A, Dowsett M, Sestak I . Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2020; 186(1):115-123. PMC: 7940308. DOI: 10.1007/s10549-020-06013-6. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Chen Z, Maricic M, Bassford T, Pettinger M, Ritenbaugh C, Lopez A . Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med. 2005; 165(5):552-8. DOI: 10.1001/archinte.165.5.552. View

10.

Dhesy-Thind S, Fletcher G, Blanchette P, Clemons M, Dillmon M, Frank E . Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017; 35(18):2062-2081. DOI: 10.1200/JCO.2016.70.7257. View

11.

Coombes R, Kilburn L, Snowdon C, Paridaens R, Coleman R, Jones S . Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007; 369(9561):559-70. DOI: 10.1016/S0140-6736(07)60200-1. View

12.

Blok E, Kroep J, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J . Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst. 2017; 110(1). DOI: 10.1093/jnci/djx134. View

13.

Sledge Jr G, Toi M, Neven P, Sohn J, Inoue K, Pivot X . The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2019; 6(1):116-124. PMC: 6777264. DOI: 10.1001/jamaoncol.2019.4782. View

14.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

15.

Goetz M, Gradishar W, Anderson B, Abraham J, Aft R, Allison K . NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw. 2019; 17(2):118-126. DOI: 10.6004/jnccn.2019.0009. View

16.

Henderson I, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S . Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21(6):976-83. DOI: 10.1200/JCO.2003.02.063. View

17.

Saha P, Regan M, Pagani O, Francis P, Walley B, Ribi K . Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017; 35(27):3113-3122. PMC: 5597253. DOI: 10.1200/JCO.2016.72.0946. View

18.

Dowsett M, Sestak I, Regan M, Dodson A, Viale G, Thurlimann B . Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol. 2018; 36(19):1941-1948. PMC: 6049399. DOI: 10.1200/JCO.2017.76.4258. View

19.

Lambertini M, Blondeaux E, Perrone F, Del Mastro L . Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer. J Clin Oncol. 2019; 38(12):1258-1267. DOI: 10.1200/JCO.19.02242. View

20.

Tjan-Heijnen V, van Hellemond I, Peer P, Swinkels A, Smorenburg C, van der Sangen M . Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol. 2017; 18(11):1502-1511. DOI: 10.1016/S1470-2045(17)30600-9. View